DPP-4

Cat. No.

A43549

CAS No.

1613458-71-1

Propyl-GSK-2793660

Propyl-GSK-2793660 is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound exhibits significant biological activity in the modulation of DPP1 activity, making it a valuable tool for studying conditions related to bronchiectasis. Its specificity and mechanism of action can facilitate research on the implications of DPP1 inhibition in various biological contexts.

Cat. No.

A43550

CAS No.

1523530-62-2

Gemigliptin hydrochloride

Synonyms: LC15-0444 hydrochloride

Gemigliptin hydrochloride is a selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), with an IC50 of 10.3 nM for human recombinant DPP-4. This compound demonstrates significant anti-glycation properties, making it a valuable tool in the study of advanced glycation end products (AGE) and their association with diabetic complications. Gemigliptin hydrochloride is primarily utilized in research focused on the modulation of glucose metabolism and the management of diabetes-related conditions.

Cat. No.

A43551

CAS No.

868771-57-7

Melogliptin

Melogliptin is a DPP-4 inhibitor that plays a crucial role in modulating glucose metabolism. By inhibiting the DPP-4 enzyme, Melogliptin enhances incretin levels, leading to improved insulin secretion and reduced glucagon levels. This compound is primarily utilized in research targeting type 2 diabetes and related metabolic disorders, providing insights into potential therapeutic strategies for glucose regulation.

Cat. No.

A43552

CAS No.

690257-74-0

MK-0626

MK-0626 is a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, exhibiting an IC50 of 6.3 nM. This compound enhances endothelial nitric oxide synthase expression and is effective in promoting neovascularization. MK-0626 demonstrates potential in mitigating hepatic steatosis and pancreatic islet injury. It is particularly relevant in research focused on diabetes and non-alcoholic fatty liver disease.

Cat. No.

A43554

CAS No.

813452-14-1

Carmegliptin (hydrochloride)

Synonyms: RO-4876904 (hydrochloride)

Carmegliptin hydrochloride is a potent DPP-IV inhibitor, exhibiting a human DPP-IV IC50 of 6.8 nM. By binding to the S1 pocket of DPP-IV, it prevents the degradation of GLP-1, leading to increased plasma insulin levels, improved glucose tolerance, and relief from hyperglycemia. This compound can serve as a valuable reagent for research into type 2 diabetes and non-insulin-dependent diabetes mellitus, providing insights into GLP-1 modulation and its effects on metabolic regulation.

Cat. No.

A43555

CAS No.

307345-51-3

Sulphostin

Sulphostin is a covalent inhibitor targeting dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 9 (DPP9), and dipeptidyl peptidase 8 (DPP8) with IC50 values of 79, 1392, and 6930 nM, respectively. By inducing phosphosulfamate modification, Sulphostin irreversibly inhibits these enzyme activities, making it a valuable tool in the study of inflammatory processes and cancer research. Its selective inhibition profile allows for detailed investigation into the roles of DPPs in various biological pathways.

Cat. No.

A43556

CAS No.

251572-86-8

P32/98 hemifumarate

P32/98 hemifumarate is a potent dipeptidyl peptidase IV (DPP4) inhibitor with a Ki value of 130 nM. It has been shown to enhance glucose tolerance, improve insulin sensitivity, and increase β-cell responsiveness in a fatty Zucker rat model. This compound is valuable for research applications focused on diabetes and metabolic disorders, providing insights into DPP4 inhibition mechanisms and their effects on glucose homeostasis.

Cat. No.

A43558

CAS No.

3020859-03-1

DPP9-IN-1

DPP9-IN-1 is a selective inhibitor of dipeptidyl peptidase 9 (DPP9) with an IC50 value of 3 nM, also exhibiting inhibition of DPP8 at 0.6 μM. This compound has been shown to induce concentration-dependent lactate dehydrogenase (LDH) release in THP-1 cells, indicating potential cytotoxic effects. DPP9-IN-1 is useful in research applications related to immune response modulation and study of DPP9-related pathways in cellular processes.

Cat. No.

A43559

CAS No.

136259-20-6

P32/98

P32/98 is a potent dipeptidyl peptidase IV (DPP4) inhibitor, exhibiting a Ki value of 130 nM. This compound is notable for its ability to enhance glucose tolerance, improve insulin sensitivity, and increase β-cell responsiveness, specifically in the fatty Zucker rat model. P32/98 is suitable for research applications targeting metabolic disorders and studying glucose homeostasis.

Cat. No.

A43560

CAS No.

855790-98-6

SGP8

SGP8 (IAVPGEVA) is a DPP4 inhibitor that demonstrates significant modulation of lipid metabolism, inflammation, and fibrosis. By inhibiting DPP4 activity, SGP8 affects the JNK-c-Jun signaling pathway and shows potential therapeutic applications in the treatment of non-alcoholic steatohepatitis (NASH). This octapeptide, derived from the hydrolysis of soybean 11S globulin, serves as a valuable tool for research in metabolic disorders and related inflammatory conditions.

Cat. No.

A43563

CAS No.

3035300-36-5

DPP-4-IN-15

DPP-4-IN-15 is a non-competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an IC50 value of 8.24 μM. This compound effectively modulates the activity of DPP-4, an enzyme involved in glucose metabolism and insulin regulation. DPP-4-IN-15 is primarily utilized in diabetes research, providing insights into the potential therapeutic effects of DPP-4 inhibition on glycemic control and related metabolic disorders.

Cat. No.

A43566

CAS No.

160219-74-9

Fluostatin A

Fluostatin A is a potent inhibitor of dipeptidyl peptidase III (DPP-III), demonstrating an IC50 value of 0.44 μg/mL with the substrate arginyl-arginine-2-naphthalene formamide. By modulating DPP-III activity, Fluostatin A plays a significant role in studies related to peptide metabolism and signaling pathways. This compound is suitable for research applications in diabetes, cardiovascular disease, and other metabolic disorders targeting DPP-III enzymatic regulation.

Cat. No.

A43567

CAS No.

1163719-08-1

AMG-222 tosylate

AMG-222 tosylate is a potent DPP-IV inhibitor, primarily employed in the investigation of type II diabetes. By modulating the activity of the DPP-IV enzyme, AMG-222 tosylate facilitates enhanced insulin secretion and improved glycemic control. This compound is valuable for research aimed at understanding the mechanisms of glucose homeostasis and developing therapeutic approaches for managing diabetes.

Cat. No.

A43568

CAS No.

158906-40-2

Fluostatin B

Fluostatin B is a dipeptidyl peptidase 3 (DPP-3) inhibitor with an IC50 value of 24 µg/mL. As a natural product derived from Streptomyces, this compound exhibits potential biological activity in modulating peptide metabolism. Fluostatin B is relevant for research applications focused on understanding DPP-3's role in various physiological processes and exploring its implications in disease states such as diabetes and cancer.

Cat. No.

A43570

CAS No.

103192-50-3

H-Gly-Pro-Hyp-OH acetate

H-Gly-Pro-Hyp-OH acetate functions as a dipeptidyl peptidase 4 (DPP-4) inhibitor, exhibiting an IC50 value of 2.51 mM. This compound has shown promise in the investigation of diabetes-related pathways and therapeutic strategies. Its ability to modulate DPP-4 activity makes it a valuable reagent for research in metabolic disorders and glucose homeostasis.

Cat. No.

A43574

CAS No.

91533-02-7

HTS13517

HTS13517 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP4), exhibiting an IC50 value of 10.73 μM. This compound is relevant for studies investigating the modulation of glucose metabolism and the regulation of incretin hormones. Its applications include diabetes research and the exploration of therapeutic strategies targeting metabolic disorders.

Cat. No.

A43575

CAS No.

1601479-87-1

Garvagliptin

Synonyms: ZYDPLA1

Garvagliptin is a selective and orally active dipeptidyl peptidase-4 (DPP4) inhibitor, achieving an IC50 of 2.99 nM against human recombinant DPP IV. Its primary mechanism facilitates the enhancement of incretin levels, thereby exhibiting antihyperglycemic effects. Garvagliptin is widely utilized in diabetes research to explore its potential in glycemic control and metabolic regulation.

Cat. No.

A51419

CAS No.

200203-20-9

HIV-1 tat Protein (1-9)

HIV-1 tat Protein (1-9) targets Dipeptidyl Peptidase IV (DP IV) and functions as an inhibitor of this enzyme. This peptide has been implicated in the immunosuppression of non-HIV-1-infected T cells, making it relevant for studies related to acquired immune deficiency syndrome (AIDS). Researchers can synthesize HIV-1 tat Protein (1-9) using the Fmoc (N-(9-fluorenyl)methoxycarbonyl) technique with peptide synthesizer 431A. It serves as a valuable reagent for investigating the mechanisms of HIV-1 pathogenesis and potential therapeutic strategies.